Boehringer Ingelheim acquires Nerio Therapeutics, strengthening immune-oncology profile
July 30, 2024Mergers and Acquisitions Boehringer Ingelheim, Nerio Therapeutics, Oncology, immuno-oncology, oncology
Biopharmaceutical company Boehringer Ingelheim has announced the acquisition of drug discovery and development company Nerio Therapeutics for up to $1.3bn, …
Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI in combination with MEKTOVI for the treatment of adult patients with advanced non-small cell lung cancer NSCLC) with a BRAFV600E mutation
July 29, 2024Clinical Trial Services BRAF mutation, CHMP, EMA, Oncology, Pierre Fabre Laboratories, colorectal cancer, european studies, non-small cell lung cancer
Pierre Fabre Laboratories has announced a positive opinion from the European Medical Association’s (EMA) Committee for Medicinal Products Human use …
CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
July 29, 2024Research and Development ADC, CHMP, Merck, Oncology, Urology, keytruda, metastatic urothelial carcinoma, unresectable urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 therapy, in combination with Padcev …
Calliditas Therapeutics announces positive phase 2b data in Primary Biliary Cholangitis trial
July 26, 2024Research and Development Calliditas, Hepatology, clinical trials, elevated liver stiffness, primary biliary cholangitis
Calliditas Therapeutics AB today announced that the phase 2b TRANSFORM trial met its primary endpoint. The trial showed statistically significant …
AC Immune’s pTau-targeting immunotherapy awarded Fast Track designation by FDA
July 26, 2024Research and Development AC Immune, Alzheimer's disease, Neurology, clinical trials, fast track designation, immunotherapy, tau protein
Clinical-stage biopharmaceutical company AC Immune announced that the US Food and Drug Administration (FDA) has granted its Alzheimer’s disease (AD) …
BioAtla gains FDA Fast Track Designation for ozuriftamab vedotin
July 25, 2024Medical Communications BioAtla, FDA, Oncology, fast track designation, ozuriftamab vedotin
BioAtla has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ozuriftamab vedotin, …
Eisai and EcoNaviSta enter dementia collaboration
July 25, 2024Business Services EcoNaviSta, Eisai, Neurology, collaboration, dementia
Eisai and EcoNaviSta have announced that they have entered into a business alliance agreement, initiating their collaboration intended to build …
Agilent to acquire BIOVECTRA for $925m
July 24, 2024Business Services Agilent, CMDO, Pharmacy, acquisition
Agilent Technologies has announced that it has signed a definitive agreement to acquire BIOVECTRA, a leading specialised contract development and …
J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression
July 24, 2024Medical Communications J&J, Johnson & Johnson, Neurology, Spravato, treatment-resistant depression
Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application (sNDA) to the US Food …
ViiV Healthcare shares data for two-drug regimen for HIV-1 maintenance therapy
July 23, 2024Research and Development GSK, HIV, HIV/AIDS, ViiV Healthcare, maintenance therapy
GSK has announced that ViiV Healthcare, a specialist HIV company predominantly owned by GSK with Pfizer and Shionogi as shareholders, …
ViroCell Biologics signs Master Services Agreement with NCI-designated cancer centre
July 23, 2024Business Services Cancer, Oncology, ViroCell Biologics, agreement
ViroCell Biologics has announced that it has signed a five-year Master Services Agreement (MSA) with a prominent US-based NCI-designated cancer …
60 Degrees Pharmaceuticals signs clinical trial agreements with sites for babesiosis study
July 22, 2024Medical Communications 60 Degrees Pharmaceuticals, Pharmacy, babesiosis, clinical trials
60 Degrees Pharmaceuticals has announced that it has signed clinical trial agreements with all three of its planned trial sites …
Results from Sanofi’s ALTUVIIIO XTEND-Kids phase 3 trial published in NEJM
July 22, 2024Research and Development Altuviiio, Haematology, Sanofi, haemophilia
Sanofi has announced that full results from the XTEND-Kids phase 3 study were published in The New England Journal of …
GSK’s application for Blenrep for MM treatment accepted for EMA review
July 19, 2024Medical Communications Blenrep, EMA, GSK, Oncology
GSK has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for Blenrep (belantamab mafodotin) …
Brainomix and Boehringer Ingelheim enter strategic partnership
July 19, 2024Research and Development Boehringer Ingelheim, Brainomix, Pharmacy, fibrosing lung disease, partnership
Brainomix has announced that it has entered into a strategic partnership with Boehringer Ingelheim for a collaborative programme surrounding the …
FDA accepts Atara Biotherapeutics’ Tab-Cel for priority review
July 18, 2024Medical Communications Atara Biotherapeutics, FDA, Virology, priority review
Atara Biotherapeutics has announced that the US Food and Drug Administration (FDA) has accepted the filing of its Biologics License …
China’s NMPA accepts Everest Medicines’ Nefecon supplementary application
July 18, 2024Medical Communications China, Everest Medicines, NMPA, Nephrology
Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has accepted the submission of a supplemental New Drug …
Loci Orthopaedics announces €12.8m series A financing
July 17, 2024Business Services Financing, Musculo-skeletal disorder, investment, loci orthopaedics
Loci Orthopaedics has announced the successful closing of an oversubscribed €12.8m series A financing, which was led by new investors …
Renalys Pharma closes ¥6bn series A financing for kidney disease treatments in Asia
July 17, 2024Business Services Financing, Nephrology, kidney disease, renalys Pharma
Renalys Pharma has announced that it has completed ¥6bn series A financing, which was led by Catalys Pacific and SR …
Camurus shares phase 3 results from ACROINNOVA 2 study
July 16, 2024Research and Development Camurus, Pharmacy, acromegaly, clinical trial, injection
Camurus has announced positive results from its 52-week phase 3 open-label ACROINNOVA 2 study, which assessed the safety and efficacy …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
